肿瘤细胞治疗研究
英文原题：Impacts of ageing on the efficacy of CAR-T cell therapy.
Impacts of ageing on the efficacy of CAR-T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
识别 CD19 的 CAR-T 细胞（19CAR-T）细胞疗法在治疗某些血液系统恶性肿瘤时已取得稳健的临床疗效，但哪些患者亚组获益最大仍不明确。
识别CD19的CAR-T 细胞（19CAR-T）细胞疗法在治疗某些血液系统恶性肿瘤时已取得显著的临床疗效，但哪些患者亚组获益最大仍不清楚。在此，我们总结了来自30项临床试验的541例接受19 CAR-T 治疗患者的数据，并分析了年轻（<44岁）、中年（45-59岁）和老年（>60岁）患者之间不同的临床反应，发现年轻患者表现出更高水平的完全缓解（CR）率。因此，我们随后总结了关注年龄对CAR-T 疗法抗肿瘤疗效影响的研究进展，并分析老年肿瘤患者CAR-T 细胞治疗后CR率低的原因，旨在为肿瘤科医生选择最适合这种癌症免疫治疗的候选患者提供提示。
Chimeric antigen receptor T cells recognizing CD19 (19CAR-T) cell therapy has achieved robust clinical efficacy when treating some hematological malignancies, but which patient subgroups benefit mostly remains elusive. Here we summarized the data of 541 patients from 30 clinical trials who underwent 19 CAR-T therapy and analyzed the different clinical responses between young (<44 years), middle-aged (45-59 years) and elderly (>60 years) patients and found that the young patients showed a higher level of complete response (CR) rate. Therefore, we then summarize the advances of studies focusing on the effects of age on anti-tumor efficacy of CAR-T therapy and analyze the reasons for the low CR rate after CAR-T cell therapy in elderly patients with tumors, aiming to provide hints for oncologists to select the most suitable candidate for this cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
